The following study was conducted by Scientists from Science for Life Laboratory, KTH – Royal Institute of Technology, Stockholm, Sweden; Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King’s College London, London, UK; Department of Medical Biology, Faculty of Medicine, Atatu¨rk University, Erzurum, Turkey; Department of Molecular and Clinical Medicine, University of Gothenburg, The Wallenberg Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Biology and Biological Engineering, Chalmers University of Technology, SE-Gothenburg, Sweden. Study is published in iScience Journal – Cell Press Publishing as detailed below.
iScience Journal – Cell Press Publishing (2020)
Current Status of COVID-19 Therapies and Drug Repositioning Applications
The rapid and global spread of a new human coronavirus (SARS-CoV-2) has produced an immediate urgency to discover promising targets for the treatment of COVID-19. Drug repositioning is an attractive approach that can facilitate the drug discovery process by repurposing existing pharmaceuticals to treat illnesses other than their primary indications. Here, we review current information concerning the global health issue of COVID-19 including promising approved drugs and ongoing clinical trials for prospective treatment options. In addition, we describe computational approaches to be used in drug repurposing and highlight examples of in silico studies of drug development efforts against SARS-CoV-2.
Source:
iScience Journal – Cell Press Publishing
URL: https://www.cell.com/iscience/fulltext/S2589-0042(20)30490-9
Citation:
Altay, O., E. Mohammadi, et al. (2020). “Current Status of COVID-19 Therapies and Drug Repositioning Applications.” iScience 23(7).
